{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"6.0","value":"2.0"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"10.0","value":"1.0"}]}],"title":"Hospitalizations"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"3.0","value":"1.0"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"3.0","value":"1.0"}]}],"title":"Emergency Room Stays"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"57.0","value":"4.0"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"34.0","value":"3.0"}]}],"title":"Outpatient Visits"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"description":"Duration of healthcare resources used during medical encounters including hospitalizations, emergency room stays, or outpatient visits was reported in days. A hospitalization was defined as at least 1 overnight stay in an Intensive Care Unit and/or non-Intensive Care Unit (acute care unit, palliative care unit, and hospice).","dispersionType":"Full Range","groups":[{"description":"Pomalidomide 4 mg, capsules, orally, once daily on Days 1 to 21 of each 28-day cycle, plus dexamethasone 40 mg, (or 20 mg if participant is aged \\>=75 years), tablets, orally, once daily on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.","id":"OG000","title":"Pomalidomide 4 mg + Dexamethasone 40 mg"},{"description":"Ixazomib 4 mg as starting dose, capsules, orally, once daily on Days 1, 8, and 15 of each 28-day cycle, with escalation to 5.5 mg at the start of Cycle 2 for participants who tolerated the 4 mg dose in Cycle 1, plus dexamethasone 20 mg (or 10 mg if participant is aged \\>=75 years), tablets, orally, once daily on Days 1, 2, 8, 9, 15, 16, 22, and 23 of every 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.","id":"OG001","title":"Ixazomib 4 mg + Dexamethasone 20 mg"}],"paramType":"MEDIAN","populationDescription":"ITT Population included all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"HU: Duration of Medical Encounters","type":"SECONDARY","unitOfMeasure":"days"}